Position in NXTC
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$135,499
-$608,010 QoQ
Shares Held
84,687
+21.6% QoQ
Ownership
1.85%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#7
of 30 holders
Holding Since
Sep 2020
10 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NXTC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026BOOTHBAY FUND MANAGEMENT, LLC holds $666,641,771 across 159 Biotechnology names. NXTC ranks #135 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
465,787 | $87,232,589 | |
| 2 | ABVX |
Abivax S.A.
|
563,367 | $75,074,286 | |
| 3 | EXEL |
Exelixis, Inc.
|
804,095 | $43,750,808 | |
| 4 | PCVX |
Vaxcyte, Inc.
|
534,163 | $31,050,895 | |
| 5 | COGT |
Cogent Biosciences, Inc.
|
692,825 | $26,812,327 | |
| 6 | CGEM |
Cullinan Therapeutics, Inc.
|
1,082,611 | $19,714,346 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
500,497 | $15,645,536 | |
| 8 | AVTX |
Avalo Therapeutics, Inc.
|
702,051 | $12,973,902 |
All Filings in NXTC
Export CSV
10 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $135,499 | 84,687 | Shares | Other | 2026-08-14 | |
| 2026-03-31 | $743,509 | 69,617 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $987,865 | 69,617 | Shares | Other | 2026-02-17 | |
| 2022-03-31 | $65,464 | 13,470 | Shares | Other | 2022-05-16 | |
| 2021-12-31 | $80,819 | 13,470 | Shares | Other | 2022-02-14 | |
| 2021-09-30 | $344,811 | 51,159 | Shares | Other | 2021-11-15 | |
| 2021-06-30 | $511,984 | 63,759 | Shares | Other | 2021-08-17 | |
| 2021-03-31 | $517,406 | 51,689 | Shares | Other | 2021-05-17 | |
| 2020-12-31 | $250,569 | 22,988 | Shares | Other | 2021-02-12 | |
| 2020-09-30 | $202,294 | 22,988 | Shares | Other | 2020-11-16 | |
| No filing history on record for this holder in this stock. | ||||||